CLDX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CLDX is not a clear buy right now for a Beginner investor focused on the long term, even with $50,000-$100,000 available. The stock has constructive analyst support and a favorable catalyst setup, but the current price action is neutral to slightly weak and there is no strong proprietary buy signal today. For an impatient buyer, this looks more like a wait-and-watch name than an immediate purchase.
The technical picture is mixed. CLDX is trading around 32.50, slightly above the previous close but below the pivot at 33.175, which suggests it is still struggling to reclaim near-term momentum. MACD histogram is -0.249 and contracting below zero, showing bearish momentum is still present, while RSI at 43.08 is neutral and does not indicate an oversold bounce. Moving averages are converging, which usually signals indecision rather than a strong trend. Key support is near 31.90 and resistance is near 34.45. Overall, the chart does not currently show a clean uptrend or a compelling entry for a beginner.
["Wells Fargo raised its price target to $54 and kept an Overweight rating, citing better expectations ahead of barzolvolimab PN data in mid-2026.", "Barclays upgraded the stock to Overweight and lifted its target to $45, highlighting faster-than-expected Phase 3 enrollment and a favorable catalyst setup.", "Wolfe Research sees a better catalyst setup in 2026 and views the valuation as depressed.", "Multiple late-2025 and 2026 pipeline updates and Phase 3/Phase 2 readouts create a catalyst-rich period.", "Long-term sentiment is supported by continued analyst optimism around barzolvolimab and mast-cell depletion biology."]
["No news in the last week, so there is no fresh event-driven catalyst right now.", "MACD is negative and weakening, showing short-term momentum is not favorable.", "The stock is below the pivot level and has not broken into a strong upward trend.", "Open interest put-call ratio of 1.28 suggests cautious positioning.", "No recent insider buying, no recent notable hedge fund accumulation, and no congress trading activity were reported.", "Goldman Sachs remains Neutral despite raising its target, which shows the Street is still mixed."]
No usable latest-quarter financial snapshot was provided, so I cannot assess revenue or EPS growth for the latest quarter season. Based on the available data, there is no financial update to support a fresh fundamental acceleration call.
Analyst sentiment has improved overall in recent months. Wells Fargo raised its target to $54 and kept Overweight on 2026-05-13, Barclays raised to $48 and kept Overweight on 2026-05-08, and Goldman Sachs increased its target to $38 but stayed Neutral. Earlier in the year, Barclays upgraded to Overweight from Underweight and Wolfe upgraded to Outperform, while Stifel remained bullish with a $68 target and Buy rating. The Wall Street view is constructive overall, with the pros emphasizing catalyst potential, enrollment progress, and a favorable risk/reward setup. The main con is that some firms, especially Goldman, still see the stock more as a hold than a must-buy.
